L&C Bio Co., Ltd

KOSDAQ 290650.KQ

L&C Bio Co., Ltd Gross Profit Margin for the year ending December 31, 2023: 47.23%

L&C Bio Co., Ltd Gross Profit Margin is 47.23% for the year ending December 31, 2023, a -8.01% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

L&C Bio Co., Ltd Gross Profit Margin for the year ending December 31, 2022 was 51.34%, a -17.57% change year over year.
L&C Bio Co., Ltd Gross Profit Margin for the year ending December 31, 2021 was 62.29%, a 5.01% change year over year.
L&C Bio Co., Ltd Gross Profit Margin for the year ending December 31, 2020 was 59.32%, a -7.35% change year over year.
L&C Bio Co., Ltd Gross Profit Margin for the year ending December 31, 2019 was 64.02%, a 1.63% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KOSDAQ: 290650.KQ

L&C Bio Co., Ltd

CEO	Mr. Chul Lee Whan
IPO Date	Nov. 1, 2018
Location	South Korea
Headquarters	Suntechcity
Employees	122
Sector	Health Care
Industries Biotechnology Cosmetics Pharmaceuticals Research & Consulting

Description

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years